Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q3 2021 · 10-Q
Revenue$3.10M$3.10M+111.6% vs Q3 2020 Net Income-$7.00M-$7.00MN/M vs Q3 2020 EPS Diluted-$1.43-$1.43N/M vs Q3 2020 Operating Income-$4,750,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,255,000— Margins · derivedOperating margin-153.4%+273.5 pt vs Q3 2020
Net margin-226.0%+238.2 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end